The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting cochlear synaptopathy (a leading cause of difficulty understanding speech in noise, tinnitus, and hyperacusis), as…
Montpellier - France – November 7th, 2024 – Cilcare, a clinical-stage biotechnology company specializing in the development of innovative therapies for inner ear disorders, is pleased to announce the appointment…
Montpellier - France – September 30th, 2024 – Cilcare, a clinical-stage biotechnology company specializing in the development of therapeutics for inner ear disorders, is pleased to announce the appointment of…
Through the ‘i-Démo’ call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government, Cilcare is further consolidating its international leadership by being the…
Montpellier and Osaka – June 6th, 2024 – Cilcare, a leading biotech company specializing in auditory sciences, is pleased to announce a landmark agreement with Shionogi, an impact-driven pharmaceutical company.…
